Travere Therapeutics, INC 10-Q quarterly reports

Travere Therapeutics announced a significant increase in net product sales, primarily driven by FILSPARI, alongside substantial growth in operating expenses and a net loss for the quarter.

Travere Therapeutics announced a significant increase in net product sales, driven by FILSPARI, and provided updates on its clinical pipeline.

Travere Therapeutics, Inc. announced significant revenue growth in the third quarter of 2025, driven by strong FILSPARI sales and milestone payments, while narrowing its net loss for the nine-month period.

Travere Therapeutics reports strong revenue growth driven by FILSPARI, significantly reducing its net loss and advancing key pipeline programs.

Travere Therapeutics' Q1 2025 shows significant revenue growth driven by FILSPARI, alongside progress in regulatory submissions and clinical trials.

Travere Therapeutics' Q3 2024 results show increased product sales driven by FILSPARI, alongside strategic pipeline advancements and a voluntary pause in a key clinical trial.

Travere Therapeutics announces Q2 2024 results, highlighting increased FILSPARI sales and progress towards full FDA approval.

Travere Therapeutics' first quarter 2024 results show increased product sales driven by FILSPARI, alongside significant R&D expenses and a strategic restructuring.